What Enterprise Therapeutics does

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company founded in 2014 that develops muco-regulatory therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases. The company's lead programs target two ion channels — ENaC and TMEM16A — to restore airway hydration and mucus clearance in cystic fibrosis (CF), COPD, severe asthma, and non-CF bronchiectasis. Its core asset, ETD001, is a novel inhaled ENaC blocker that in May 2026 became the first investigational ENaC blocker to deliver clinically relevant and statistically significant improvement in lung function in a Phase 2 trial (3.4 percentage point improvement in ppFEV1, p=0.0053). A second program, ETD002 (first-in-class TMEM16A potentiator), was fully divested to Roche in October 2020 for £75 million upfront plus contingent milestones. Drug discovery is supported by the company's proprietary Bronchosphere platform, a miniaturized human airway model used for high-throughput target identification and compound screening, with medicinal chemistry collaboration through Evotec and academic partnerships with the University of Sussex, UNC, and University of Miami.

The company generates revenue through pharmaceutical licensing, partnership divestitures, and non-dilutive grant funding rather than direct product sales. The £75 million upfront from Roche for the TMEM16A portfolio in 2020 is the only material disclosed commercial transaction, supplemented by a £7 million Cystic Fibrosis Foundation Therapeutics Development Award and a Cystic Fibrosis Trust grant for bronchosphere research. Enterprise's go-to-market approach targets regulatory engagement (FDA Rare Pediatric Disease Designation for ETD001 granted September 2024, EMA interactions), clinical investigator networks across the UK, Germany, France, and Italy, and scientific communications through peer-reviewed publications in The Journal of Cystic Fibrosis, European Journal of Medicinal Chemistry, and American Journal of Respiratory and Critical Care Medicine, plus presentations at NACFC, ECFS, and Gordon Research Conferences. The company has raised approximately £62 million in equity from a syndicate of specialist life-sciences investors including Epidarex Capital, Versant Ventures, Novartis Venture Fund, Forbion, IP Group, and Panakes Partners, and operates a wholly-owned Italian subsidiary (Enterprise Therapeutics S.R.L.) to support R&D and clinical operations across Europe.

Name

Enterprise Therapeutics

Legal name

Enterprise Therapeutics Limited

Website

https://enterprisetherapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Enterprise Therapeutics is a UK-based clinical-stage biopharmaceutical company developing novel muco-regulatory therapies (ENaC blockers and TMEM16A potentiators) for cystic fibrosis, COPD, severe asthma, and non-CF bronchiectasis, with lead asset ETD001 having achieved positive Phase 2 results in 2026.

Ownership category

akta.pro rank

Product category

Respiratory Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Respiratory disease therapeutics
• Cystic fibrosis treatments
• Muco-regulatory drug discovery
• Inhaled ENaC blockers
• Ion channel modulators

Headquarters

HQ city

Falmer

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Licensing: Pre-revenue clinical stage biopharmaceutical company. The company develops novel therapies through clinical trials with the intent to commercialize or license. TMEM16A potentiator programme (ETD002) was acquired by Roche for £75 million upfront with additional milestone payments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies that target ion channels (ENaC and TMEM16A) to restore airway mucus hydration and clearance in respiratory diseases. Its lead asset, ETD001, is a first-in-class inhaled ENaC blocker for cystic fibrosis that achieved positive Phase 2 results. The company also operates the Bronchosphere technology platform, a miniaturized model of the human airway used for high-throughput drug and target discovery.

Product overview

Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing muco-regulatory therapies for respiratory diseases. The company's portfolio includes ETD001, a novel inhaled ENaC blocker that achieved positive Phase 2 results for cystic fibrosis, and the Bronchosphere platform technology for drug discovery. The TMEM16A potentiator programme (ETD002) was acquired by Roche. The company targets underlying mechanisms of mucus congestion through ion channel modulation to enhance clearance and restore lung function in CF, COPD, and severe asthma.

Differentiator

Problem solved

Functional benefit

Products and services

• ETD001

Quantifiable outcome

• 3.4% points improvement in ppFEV1 (p=0.0053) compared to placebo in 28-day Phase 2 trial
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, moderate and minor.

• EvoteccoreStrategic or Co-development Partner · 19 November 2024Medicinal chemistry work described in European Journal of Medicinal Chemistry publication was carried out in collaboration with Evotec, supporting optimization of ENaC blocker compounds leading to ETD001.
• Roche/GenentechcoreStrategic or Co-development Partner · 7 October 2020Roche fully acquired Enterprise's TMEM16A potentiator portfolio, to be developed by Genentech. Enterprise received £75 million upfront payment with eligibility for additional contingent milestone payments. Portfolio included ETD002, a first-in-class TMEM16A potentiator in Phase 1.
• University of SussexcoreStrategic or Co-development Partner · 8 January 2020Enterprise has close working relationship with School of Life Sciences at University of Sussex. Collaborated on TMEM16A research published in American Journal of Respiratory and Critical Care Medicine along with Sussex Drug Discovery Centre researchers.
• University of North CarolinamoderateStrategic or Co-development Partner · 8 January 2020Research collaboration with Brian Button from UNC Chapel Hill on TMEM16A potentiator programme and mucus clearance research.
• University of MiamimoderateStrategic or Co-development Partner · 8 January 2020Research collaboration with Juan Sabater from Mount Sinai Medical Center, University of Miami on TMEM16A research.
• The DPO CentreminorOthersEnterprise Therapeutics Ltd's EU Representative is The DPO Centre, based in Paris, France, providing data protection officer services for EU compliance.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vertex Pharmaceuticals: Vertex is the dominant cystic fibrosis franchise holder with Trikafta/Kaftrio and other CFTR modulators treating ~90% of CF patients. Enterprise's ETD001 targets the residual CF population not benefiting from Vertex's therapies, making Vertex the most direct competitive benchmark.
• Galapagos NV: Galapagos has historically been active in cystic fibrosis drug development with CFTR modulators and has broader respiratory pipeline interest. Dr Niyati Prasad, Enterprise's CMO, previously held leadership roles at Galapagos.
• Parion Sciences: Parion developed epithelial sodium channel (ENaC) blockers for respiratory diseases and was acquired by Vertex. Direct mechanistic overlap with Enterprise's ETD001 (also an ENaC inhibitor) makes Parion a precedent competitor in the same pharmacological class.
• Insmed: Insmed develops respiratory therapeutics, notably brensocatib for non-CF bronchiectasis, an indication Enterprise plans to enter. Both companies target mucus-related and chronic respiratory diseases with late-stage clinical assets.

Emerging players

• Arcturus Therapeutics: Arcturus is developing CFTR mRNA therapeutics (ARCT-032) for cystic fibrosis, targeting patients not responsive to modulators. Overlaps with Enterprise's addressable patient population through a different therapeutic modality (mRNA vs. ENaC inhibition).
• TFF Pharmaceuticals: TFF Pharmaceuticals develops inhaled drug formulations for respiratory diseases including CF using thin-film freezing technology. Overlaps with Enterprise's inhaled delivery approach for respiratory therapeutics targeting mucus-related diseases.
• 4D Molecular Therapeutics: 4DMT is developing aerosolized gene therapies for cystic fibrosis lung disease, targeting the same CF population underserved by modulators. Represents an emerging modality-based competitor in the residual CF segment.
• Eloxx Pharmaceuticals: Eloxx has been developing therapies for rare CF mutations including nonsense mutations, partially overlapping with Enterprise's addressable population in CF. Both target patients with limited or no therapeutic options.

Broad incumbents

• AbbVie: AbbVie has a major respiratory franchise including therapies for asthma and COPD. Dr Janet Hammond, Enterprise's NED, was previously VP and Head of Infectious Diseases and General Medicine at AbbVie, indicating close familiarity.
• Roche/Genentech: Roche acquired Enterprise's TMEM16A potentiator portfolio for £75M upfront. As the developer of the divested ETD002 program and a global pharma leader with respiratory interests, Roche is both a historical partner and a potential acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/9301181

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enterprise Therapeutics